Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs

World Journal of Gastroenterology

Volumn , Issue 29, 2014, Pages 9699-9715

  Saniabadi, Abbi R ^a,b   Tanaka, Tomotaka ^c   Ohmori, Toshihide ^d   Sawada, Koji ^e   Yamamoto, Takayuki ^f   Hanai, Hiroyuki ^g  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

^c Akitsu Prefectural Hospital   (Japan)

^d Ohmori Gastrointestinal Clinic   (Japan)

^e Ikoma General and Gastroenterological Clinic   (Japan)

^f MIE UNIVERSITY   (Japan)

^g Hamamatsu South Hospital   (Japan)

Author keywords

Adsorptive granulocytes monocytes apheresis; Complement activation fragments; Corticosteroid sparing effect; Inflammatory bowel disease; Myeloid lineage leucocytes; Treating inflammatory bowel disease without drugs

Indexed keywords

AZATHIOPRINE; CD14 ANTIGEN; CD16 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; COMPLEMENT RECEPTOR; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 23; L SELECTIN; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; AUTACOID;

ADSORPTIVE LEUCOCYTAPHERESIS; ANTIGEN ANTIBODY COMPLEX; ARTICLE; COLON RESECTION; COLONOSCOPY; CROHN DISEASE; CYTAPHERESIS; DIGESTIVE TRACT ENDOSCOPY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG RESPONSE; DRUG SAFETY; HEALTH CARE COST; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASE; INTESTINE POLYP; MEDICAL PRACTICE; NATURAL KILLER CELL; NEUTROPHIL COUNT; NONHUMAN; PHLEBOTOMY; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REMISSION; RISK FACTOR; SURVIVAL; SURVIVAL TIME; TARGET CELL; ULCERATIVE COLITIS; ADOLESCENT DISEASE; APHERESIS; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL LINEAGE; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COLON MUCOSA; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; EUROPEAN UNION; GRANULOCYTE MONOCYTE APHERESIS; LEUKOCYTE; LONG TERM CARE; MORBIDITY; MULTICENTER STUDY (TOPIC); THERAPY EFFECT; BLOOD; COLITIS, ULCERATIVE; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOLOGY; LEUKAPHERESIS; METABOLISM; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

COLITIS, ULCERATIVE; COLONOSCOPY; COST-BENEFIT ANALYSIS; CROHN DISEASE; CYTOKINES; HEALTH CARE COSTS; HUMANS; INFLAMMATION MEDIATORS; LEUKAPHERESIS; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84905842820     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.9699     Document Type: Article

References (117)

1. Selby W . The natural history of ulcerative colitis. Baillieres Clin Gastroenterol 1997; 11: 53-64 [PMID: 9192060 DOI: 10.1016/S0950-3528(97)90053-1]
2. Loftus CG, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ, Sandborn WJ. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007; 13: 254-261 [PMID: 17206702 DOI: 10.1002/ibd.20029]
3. Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136: 65-80 [PMID: 19026645 DOI: 10.1053/j.gastro.2008.10.080]
4. Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML, Appleyard CB, Jobin C. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis 2011; 17: 289-297 [PMID: 20564535 DOI: 10.1002/ibd.21366]
5. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]
6. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-86 [PMID: 2563951 DOI: 10.1136/bmj.298.6666.82]
7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-1629 [PMID: 3317057 DOI: 10.1056/NEJM198712243172603]
8. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845 [PMID: 8196726 DOI: 10.1056/NEJM199406303302601]
9. Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Batts KP, Lawson GM. Cyclosporine enemas for treatmentresistant, mildly to moderately active, left-sided ulcerative colitis. Am J Gastroenterol 1993; 88: 640-645 [PMID: 8480724]
10. Travis SP, Higgins PD, Orchard T, Van Der Woude CJ, Panaccione R, Bitton A, O'Morain C, Panés J, Sturm A, Reinisch W, Kamm MA, D'Haens G. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 34: 113-124 [PMID: 21615435 DOI: 10.1111/j.1365-2036.2011.04701.x]
11. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444 [PMID: 1248701]
12. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-1070 [PMID: 4135487 DOI: 10.1016/S0140-6736(74)90552-2]
13. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology 2004; 126: 1582-1592 [PMID: 15168369 DOI: 10.1053/j.gastro.2004.02.071]
14. Hyde GM, Thillainayagam AV, Jewell DP. Intravenous cyclosporin as rescue therapy in severe ulcerative colitis: time for a reappraisal? Eur J Gastroenterol Hepatol 1998; 10: 411-413 [PMID: 9619388 DOI: 10.1097/00042737-199805000-00010]
15. Hanauer SB. Can cyclosporine go it alone in severe ulcerative colitis? Curr Gastroenterol Rep 2001; 3: 455-456 [PMID: 11696281 DOI: 10.1007/s11894-001-0064-x]
16. O'Keefe SJ. Nutrition and gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 220: 52-59 [PMID: 8898436 DOI: 10.3109/00365529609094750]
17. Kozuch PL, Hanauer SB. Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 2008; 14: 354-377 [PMID: 18200659 DOI: 10.3748/wjg.14.354]
18. Taffet SL, Das KM. Sulfasalazine. Adverse effects and desensitization. Dig Dis Sci 1983; 28: 833-842 [PMID: 6136396 DOI: 10.1007/BF01296907]
19. Present DH . How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000; 6: 48-57; discussion 58 [PMID: 10701150 DOI: 10.1097/00054725-200002000-00009]
20. Serkova NJ, Christians U, Benet LZ. Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv 2004; 4: 97-107 [PMID: 15087483 DOI: 10.1124/mi.4.2.7]
21. Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol 1995; 20: 280-284 [PMID: 7665814 DOI: 10.1097/00004836-199506000-00004]
22. Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, Shima C, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 2003; 7: 48-59 [PMID: 12921115 DOI: 10.1046/j.1526-0968.2003.00012.x]
23. Saniabadi AR, Hanai H, Suzuki Y, Ohmori T, Sawada K, Yoshimura N, Saito Y, Takeda Y, Umemura K, Kondo K, Ikeda Y, Fukunaga K, Nakashima M, Beretta A, Bjarnason I, Lofberg R. Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjunct or an alternative to drug therapy? J Clin Apher 2005; 20: 171-184 [PMID: 15892107 DOI: 10.1002/jca.20046]
24. Lefkowitz DL, Mills K, Lefkowitz SS, Bollen A, Moguilevsky N. Neutrophil-macrophage interaction: a paradigm for chronic inflammation. Med Hypotheses 1995; 44: 58-62 [PMID: 7776904 DOI: 10.1016/0306-9877(95)90303-8]
25. McCarthy DA, Rampton DS, Liu YC. Peripheral blood neutrophils in inflammatory bowel disease: morphological evidence of in vivo activation in active disease. Clin Exp Immunol 1991; 86: 489-493 [PMID: 1684141 DOI: 10.1111/j.1365-2249.1991.tb02958.x]
26. Brannigan AE, O'Connell PR, Hurley H, O'Neill A, Brady HR, Fitzpatrick JM, Watson RW. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 2000; 13: 361-366 [PMID: 10807010 DOI: 10.1097/00024382-200005000-00003]
27. Schreiber S, Nikolaus S, Hampe J, Hämling J, Koop I, Groessner B, Lochs H, Raedler A. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353: 459-461 [PMID: 9989717 DOI: 10.1016/S0140-6736(98)03339-X]
28. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000; 51: 289-298 [PMID: 10774465 DOI: 10.1146/annurev.med.51.1.289]
29. Neurath MF . IL-23: a master regulator in Crohn disease. Nat Med 2007; 13: 26-28 [PMID: 17206128 DOI: 10.1038/nm0107-26]
30. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-135 [PMID: 7797011 DOI: 10.1016/0016-5085(95)90277-5]
31. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050516]
32. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-3158 [PMID: 12483718 DOI: 10.1002/art.10679]
33. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of antitumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009; 61: 486-504 [PMID: 19628303 DOI: 10.1016/j.jaad.2008.10.060]
34. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One 2012; 7: e30275 [PMID: 22272322]
35. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995; 16: 21-26 [PMID: 7880385 DOI: 10.1016/0167-5699(95)80066-2]
36. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation. Gut 1998; 42: 470-476 [PMID: 9616306 DOI: 10.1136/gut.42.4.470]
37. Abel JJ, Rowntree LG, Turner BB. On the removal of diffusable substances from the circulating blood by means of dialysis. Transactions of the Association of American Physicians, 1913. Transfus Sci 1990; 11: 164-165 [PMID: 10160880]
38. Goldfinger D, Capostagno V, Lowe C, Sacks HJ, Gatti RA. Use of long-term leukapheresis in the treatment of chronic lymphocytic leukemia. Transfusion 1980; 20: 450-454 [PMID: 6773192]
39. Lazarus HM, Cohen SB, Clegg DO, Menitove JE, Sorin SB, Hinkle S, Markenson JA, Saal S, Goodnough LT, Fleischmann RM. Selective in vivo removal of rheumatoid factor by an extracorporeal treatment device in rheumatoid arthritis patients. Transfusion 1991; 31: 122-128 [PMID: 1996481 DOI: 10.1046/j.1537-2995.1991.31291142942.x]
40. Eshleman JR, Silberstein LE. The development of selective plasmapheresis as a means for specific therapeutic intervention. Transfusion 1991; 31: 96-98 [PMID: 1996491 DOI: 10.1046/j.1537-2995.1991.31291142958.x]
41. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001; 16: 1-9 [PMID: 11309823 DOI: 10.1002/jca.1000]
42. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004; 49: 565-571 [PMID: 15185858 DOI: 10.1023/B:DDAS.0000026299.43792.ae]
43. Cohen RD . Treating ulcerative colitis without medica-tions - " look mom, no drugs!". Gastroenterology 2005; 128: 235-236 [PMID: 15633142 DOI: 10.1053/j.gastro.2004.11.024]
44. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Kikuch K, Saniabadi AR. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004; 70: 36-44 [PMID: 15297776 DOI: 10.1159/000080079]
45. Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010; 34: 645-648 [PMID: 20971590 DOI: 10.1016/j.gcb.2010.09.003]
46. Hanai H, Watanabe F, Saniabadi AR, Matsushitai I, Takeuchi K, Iida T. Therapeutic efficacy of granulocyte and monocyte adsorption apheresis in severe active ulcerative colitis. Dig Dis Sci 2002; 47: 2349-2353 [PMID: 12395908 DOI: 10.1023/A:1020159932758]
47. Aoki H, Nakamura K, Yoshimatsu Y, Tsuda Y, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y. Adacolumn selective leukocyte adsorption apheresis in patients with active ulcerative colitis: clinical efficacy, effects on plasma IL-8, and expression of Toll-like receptor 2 on granulocytes. Dig Dis Sci 2007; 52: 1427-1433 [PMID: 17394078 DOI: 10.1007/s10620-006-9406-8]
48. Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic leukocytapheresis for inflammatory bowel disease. Transfus Apher Sci 2007; 37: 191-200 [PMID: 17974479 DOI: 10.1016/j.transci.2007.08.003]
49. Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol 2010; 34: 687-695 [PMID: 20934287 DOI: 10.1016/j.gcb.2010.08.007]
50. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003; 1: 28-35 [PMID: 15017514 DOI: 10.1053/jcgh.2003.50005]
51. Hanai H . Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12: 7568-7577 [PMID: 17171783]
52. Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006; 51: 2031-2038 [PMID: 17004123 DOI: 10.1007/s10620-006-9199-9]
53. Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008; 40: 731-736 [PMID: 18387860 DOI: 10.1016/j.dld.2008.02.012]
54. Heimann TM, Aufses AH. The role of peripheral lymphocytes in the prediction of recurrence in Crohn's disease. Surg Gynecol Obstet 1985; 160: 295-298 [PMID: 3983792]
55. Powrie F, Read S, Mottet C, Uhlig H, Maloy K. Control of immune pathology by regulatory T cells. Novartis Found Symp 2003; 252: 92-98; discussion 98-105, 106-114 [PMID: 14609214 DOI: 10.1002/0470871628.ch7]
56. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology 2005; 128: 1868-1878 [PMID: 15940622 DOI: 10.1053/j.gastro.2005.03.043]
57. Uhlig HH, Powrie F. The role of mucosal T lymphocytes in regulating intestinal inflammation. Springer Semin Immunopathol 2005; 27: 167-180 [PMID: 15959782 DOI: 10.1007/s00281-005-0206-6]
58. Liu H, Hu B, Xu D, Liew FY. CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4. J Immunol 2003; 171: 5012-5017 [PMID: 14607897]
59. Huber S, Schramm C, Lehr HA, Mann A, Schmitt S, Becker C, Protschka M, Galle PR, Neurath MF, Blessing M. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol 2004; 173: 6526-6531 [PMID: 15557141]
60. Kanai T, Watanabe M. Clinical application of human CD4+ CD25+ regulatory T cells for the treatment of inflammatory bowel diseases. Expert Opin Biol Ther 2005; 5: 451-462 [PMID: 15934825 DOI: 10.1517/14712598.5.4.451]
61. Yokoyama Y, Fukunaga K, Fukuda Y, Tozawa K, Kamikozuru K, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Demonstration of low-regulatory CD25High+CD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007; 52: 2725-2731 [PMID: 17404876 DOI: 10.1007/s10620-006-9560-z]
62. Hiraishi K, Takeda Y, Shiobara N, Shibusawa H, Jimma F, Kashiwagi N, Saniabadi AR, Adachi M. Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003; 7: 334-340 [PMID: 12924609 DOI: 10.1046/j.1526-0968.2003.00049.x]
63. D'Arrigo C, Candal-Couto JJ, Greer M, Veale DJ, Woof JM. Human neutrophil Fc receptor-mediated adhesion under flow: a hollow fibre model of intravascular arrest. Clin Exp Immunol 1995; 100: 173-179 [PMID: 7535210 DOI: 10.1111/j.1365-2249.1995.tb03620.x]
64. Lerebours E, Bussel A, Modigliani R, Bastit D, Florent C, Rabian C, René E, Soulé JC. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1994; 107: 357-361 [PMID: 8039612]
65. Kanai T, Hibi T, Watanabe M. The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease. Expert Opin Biol Ther 2006; 6: 453-466 [PMID: 16610976 DOI: 10.1517/14712598.6.5.453]
66. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004; 36: 811-817 [PMID: 15646427 DOI: 10.1016/j.dld.2004.08.004]
67. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 2010; 16: 1905-1911 [PMID: 20310015 DOI: 10.1002/ibd.21260]
68. Takayama T, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yajima T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohns Colitis 2013; 7: e49-e54 [PMID: 22633997 DOI: 10.1016/j.crohns.2012.05.005]
69. Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009; 41: 570-577 [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020]
70. Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012; 6: 750-755 [PMID: 22398094 DOI: 10.1016/j.crohns.2011.12.009]
71. Kato S, Hosomi E, Amano F, Kobayashi T, Kani K, Yamamoto R, Ogawa T, Matsuda A, Sato Y, Izaki S, Mitarai T, Yakabi K. The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. J Crohns Colitis 2012; 6: 787-791 [PMID: 22386738 DOI: 10.1016/j.crohns.2012.02.005]
72. Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007; 39: 626-633 [PMID: 17532273 DOI: 10.1016/j.dld.2007.04.007]
73. Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012; 47: 49-55 [PMID: 21915624 DOI: 10.1007/s00535-011-0464-0]
74. Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol 2013; 13: 27 [PMID: 23399416 DOI: 10.1186/1471-230X-13-27]
75. Tanaka T, Sugiyama S, Goishi H, Kajihara T, Akagi M, Miura T. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. BMC Gastroenterol 2013; 13: 130 [PMID: 23961883 DOI: 10.1186/1471-230X-13-130]
76. Tomomasa T, Kobayashi A, Kaneko H, Mika S, Maisawa S, Chino Y, Syou H, Yoden A, Fujino J, Tanikawa M, Yamashita T, Kimura S, Kanoh M, Sawada K, Morikawa A. Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci 2003; 48: 750-754 [PMID: 12741466 DOI: 10.1023/A: 1022892927121]
77. Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol 2013; 13: 41 [PMID: 23452668 DOI: 10.1186/1471-230X-13-41]
78. Panés J, Guilera M, Ginard D, Hinojosa J, González-Carro P, González-Lara V, Varea V, Domènech E, Badia X. Treatment cost of ulcerative colitis is apheresis with Adacolumn costeffective? Dig Liver Dis 2007; 39: 617-625 [PMID: 17531555 DOI: 10.1016/j.dld.2007.03.007]
79. Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Ost A, Hittel N, Saniabadi A, Löfberg R. Downregulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006; 21: 493-504 [PMID: 16538495 DOI: 10.1007/s00384-005-0069-2]
80. Ruuska T, Wewer V, Lindgren F, Malmborg P, Lindquist M, Marthinsen L, Browaldh L, Casswall T, Kalliomäki M, Grönlund J. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives. Inflamm Bowel Dis 2009; 15: 1049-1054 [PMID: 19137602 DOI: 10.1002/ibd.20859]
81. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up. J Gastroenterol Hepatol 2008; 23: 1678-1682 [PMID: 18823440 DOI: 10.1111/j.1440-1746.2008.05595]
82. Kruis W, Dignass A, Steinhagen-Thiessen E, Morgenstern J, Mössner J, Schreiber S, Vecchi M, Malesci A, Reinshagen M, Löfberg R. Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J Gastroenterol 2005; 11: 7001-7006 [PMID: 16437606]
83. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis 2007; 39: 430-434 [PMID: 17379588 DOI: 10.1016/j.dld.2007.01.001]
84. Caprilli R, D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 2007; 39: 435-437 [PMID: 17379590 DOI: 10.1016/j.dld.2007.02.003]
85. Domènech E, Hinojosa J, Esteve-Comas M, Gomollón F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004; 20: 1347-1352 [PMID: 15606397 DOI: 10.1111/j.1365-2036.2004.02288.x]
86. Maiden L, Takeuchi K, Baur R, Bjarnason I, O'Donohue J, Forgacs I, Chung-Faye G, Sanderson J, Bjarnason I. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis 2008; 14: 1413-1418 [PMID: 18521900 DOI: 10.1002/ibd.20505]
87. Lindberg A, Eberhardson M, Karlsson M, Karlén P. Longterm follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol 2010; 10: 73 [PMID: 20604939 DOI: 10.1186/1471-230X-10-73]
88. Cabriada JL, Domènech E, Ibargoyen N, Hernández V, Clofent J, Ginard D, Gutiérrez-Ibarluzea I, Hinojosa J. Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry. J Gastroenterol 2012; 47: 359-365 [PMID: 22105230 DOI: 10.1007/s00535-011-0499-2]
89. Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocytemonocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther 2010; 31: 1286-1295 [PMID: 20331579 DOI: 10.1111/j.1365-2036.2010.04295.x]
90. Bresci G, Romano A, Mazzoni A, Scatena F, Altomare E, Capria A, Sacco R. Feasibility and safety of granulocytapheresis in Crohn's disease: a prospective cohort study. Gastroenterol Clin Biol 2010; 34: 682-686 [PMID: 21075574 DOI: 10.1016/j.gcb.2010.09.009]
91. Sacco R, Romano A, Mazzoni A, Bertini M, Federici G, Metrangolo S, Parisi G, Nencini C, Giampietro C, Bertoni M, Tumino E, Scatena F, Bresci G. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study. J Crohns Colitis 2013; 7: e692-e697 [PMID: 23870727 DOI: 10.1016/j.crohns.2013.06.012]
92. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandervoort MK, Hanauer S. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008; 135: 400-409 [PMID: 18602921 DOI: 10.1053/j.gastro.2008.04.023]
93. Sands BE, Katz S, Wolf DC, Feagan BG, Wang T, Gustofson LM, Wong C, Vandervoort MK, Hanauer S. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut 2013; 62: 1288-1294 [PMID: 22760005 DOI: 10.1136/gutjnl-2011-300995]
94. Schwartz D, Ferguson JR. Current pharmacologic treatment paradigms for inflammatory bowel disease and the potential role of granulocyte/monocyte apheresis. Curr Med Res Opin 2007; 23: 2715-2728 [PMID: 17894921 DOI: 10.1185/030079907X233241]
95. Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol 2007; 41: 874-888 [PMID: 18090155 DOI: 10.1097/MCG.0b013e3180479435]
96. Sandborn WJ . Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12 Suppl 1: S15-S21 [PMID: 16378006 DOI: 10.1097/01.MIB.0000195387.26892.22]
97. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol 2003; 98: 511-512 [PMID: 12591086 DOI: 10.1111/j.1572-0241.2003.07251.x]
98. Fukuda Y, Matsui T, Suzuki Y, Kanke K, Matsumoto T, Takazoe M, Matsumoto T, Motoya S, Honma T, Sawada K, Yao T, Shimoyama T, Hibi T. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol 2004; 39: 1158-1164 [PMID: 15622479 DOI: 10.1007/s00535-004-1465-z]
99. Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009; 104: 2990-2995 [PMID: 19724269 DOI: 10.1038/ajg.2009.453]
100. Yamamoto T, Umegae S, Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol 2011; 46: 1003-1009 [PMID: 21681409 DOI: 10.1007/s00535-011-0428-4]
101. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22 [PMID: 10889150 DOI: 10.1053/gast.2000.8523]
102. Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, Sato Y, Kasuga N, Nakamura T. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 2004; 49: 1438-1443 [PMID: 15481316]
103. Ohmori T, Yamagiwa A, Nakamura I, Nishikawa K, Saniabadi AR. Treatment of pyoderma gangrenosum associated with Crohn's disease. Am J Gastroenterol 2003; 98: 2101-2102 [PMID: 14499797 DOI: 10.1111/j.1572-0241.2003.07657.x]
104. Kanekura T, Maruyama I, Kanzaki T. Granulocyte and monocyte adsorption apheresis for pyoderma gangrenosum. J Am Acad Dermatol 2002; 47: 320-321 [PMID: 12140486 DOI: 10.1067/mjd.2002.120597]
105. Kanekura T, Yoshii N, Yonezawa T, Kawabata H, Saruwatari H, Kanzaki T. Treatment of pustular psoriasis with granulocyte and monocyte adsorption apheresis. J Am Acad Dermatol 2003; 49: 329-332 [PMID: 12894091 DOI: 10.1067/S0190-9622(03)00795-3]
106. Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for pustular psoriasis. Ther Apher Dial 2008; 12: 13-18 [PMID: 18257807 DOI: 10.1111/j.1744-9987.2007.00536]
107. Ikeda S, Takahashi H, Suga Y, Eto H, Etoh T, Okuma K, Takahashi K, Kanbara T, Seishima M, Morita A, Imai Y, Kanekura T. Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis. J Am Acad Dermatol 2013; 68: 609-617 [PMID: 23332516 DOI: 10.1016/j.jaad.2012.09.037]
108. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, Espevik T, Ziegler-Heitbrock L. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-3542 [PMID: 11907116]
109. Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Nagata S, Takai K. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008; 103: 1210-1216 [PMID: 18177452 DOI: 10.1111/j.1572-0241.2007.01714]
110. Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004; 99: 1532-1538 [PMID: 15307873 DOI: 10.1111/j.1572-0241.2004.30432.x]
111. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-1561 [PMID: 8393046]
112. Hanai H, Iida T, Yamada M, Sato Y, Takeuchi K, Tanaka T, Kondo K, Kikuyama M, Maruyama Y, Iwaoka Y, Nakamura A, Hirayama K, Saniabadi AR, Watanabe F. Effects of adacolumn selective leukocytapheresis on plasma cytokines during active disease in patients with active ulcerative colitis. World J Gastroenterol 2006; 12: 3393-3399 [PMID: 16733857]
113. Takeda Y, Shiobara N, Saniabadi AR, Adachi M, Hiraishi K. Adhesion dependent release of hepatocyte growth factor and interleukin-1 receptor antagonist from human blood granulocytes and monocytes: evidence for the involvement of plasma IgG, complement C3 and beta2 integrin. Inflamm Res 2004; 53: 277-283 [PMID: 15241561 DOI: 10.1007/s00011-004-1253-5]
114. Dinarello CA, Thompson RC. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404-410 [PMID: 1838480 DOI: 10.1016/0167-5699(91)90142-G]
115. Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, Hayashi K, Tsubouchi H. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther 2003; 307: 146-151 [PMID: 12954797 DOI: 10.1124/jpet.103.054106]
116. Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis 2006; 12: 719-726 [PMID: 16917227 DOI: 10.1097/00054725-200608000-00008]
117. Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011; 163: 50-58 [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279]